FDA approves Enhertu for two HER2-positive early breast cancer indications

Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals

Enhertu’s market conquest is continuing apace. | Already tracking at $5 billion in annual sales, Enhertu has secured two new FDA approvals to treat early breast cancer. But while arriving nearly two months early, the…